Extranodal Lymphoma — Trials

Extranodal Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

263 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 18
Ph III recruiting: 1
Growth YoY: —
Industry share: 13%
Top sponsor: Ruijin Hospital
Termination share: 32.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (43)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01408043	Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma	terminated	N/A	25	Case Comprehensive Cancer CenterOTHER	1	Jun 14, 2019	clinicaltrials
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	terminated	N/A	1	Fred Hutchinson Cancer CenterOTHER	1	Jun 28, 2017